The global healthcare sector is still suffering, facing some challenges. One of the major issues is the rising cost of healthcare, which includes the procurement of drugs and medical devices, equipment maintenance, and the recruitment of professional medical staff. This high cost can create significant financial pressure on both individuals and healthcare systems. /p>
But the rapid pace of technological advancements in the healthcare is transforming the industry. The boom of weight loss drugs are definitely changing the landscape of healthcare sector, Novo Nordisk and Eli Lilly are absolutely the dominant players and beneficiaries of the boom. And other drugmakers start to emulate the two-horse success, have been scrambling to join the race, which could be worth tens of billions in less than a decade.
Large drugmakers such as Pfizer— which has a widely followed but so far ill-fated weight loss drug program — Amgen, Roche and AstraZeneca also outlined their strategies for joining the market. Meanwhile, Bayer said in an interview that the company is hesitant to enter the obesity market on its own, but it may partner with other companies.
The next entrants into the booming market have a key window of opportunity in the coming years: Goldman Sachs analysts expect 15 million U.S. adults to be on obesity medications by 2030.
If you want to know more details to provide support for your investment and business activities, this financial report that we have selected for you can give you what you want, please subscribe to read it. FORESIGHT which is the preeminent internal reference about equity markets, will provide more forward-looking and compelling investment suggestions to investors.
Subscribe to -unlock this article
Audience
per year
Subscriber